Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.

Chirag NepalColm J O'RourkeDouglas V N P OliveiraAndrzej TarantaSteven ShemaPrson GautamJulien CalderaroAndrew BarbourChiara RaggiKrister WennerbergXin W WangAnja LautemLewis Rowland Roberts Jesper B Andersen

Published in: Hepatology (Baltimore, Md.) (2018)

Stratification of intrahepatic cholangiocarcinoma patients based on occurrence of mutations in three classifier genes (IDH, KRAS, TP53) revealed unique oncogenic programs (mutational, structural, epimutational) that influence pharmacologic response in drug repositioning protocols; this genome dissection approach highlights the potential of individual mutations to induce extensive molecular heterogeneity and could facilitate advancement of therapeutic response in this dismal disease. (Hepatology 2018).

Keyphrases

genome wide
single cell
end stage renal disease
transcription factor
newly diagnosed
ejection fraction
chronic kidney disease
public health
emergency department
gene expression
copy number
single molecule
dna methylation
patient reported outcomes
climate change
adverse drug
high grade